Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ultraviolet Therapy | 1 | 2020 | 1 | 0.740 |
Why?
|
| Keratitis | 1 | 2020 | 2 | 0.740 |
Why?
|
| Eye Infections, Bacterial | 1 | 2020 | 3 | 0.740 |
Why?
|
| Riboflavin | 1 | 2020 | 24 | 0.730 |
Why?
|
| Photosensitizing Agents | 1 | 2020 | 49 | 0.710 |
Why?
|
| Collagen | 1 | 2020 | 172 | 0.680 |
Why?
|
| Obesity | 6 | 2015 | 1067 | 0.590 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 111 | 0.560 |
Why?
|
| Cluster Analysis | 1 | 2016 | 195 | 0.550 |
Why?
|
| Risk Reduction Behavior | 3 | 2015 | 127 | 0.540 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 664 | 0.540 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 104 | 0.470 |
Why?
|
| Adenoma | 2 | 2012 | 89 | 0.450 |
Why?
|
| Colorectal Neoplasms | 3 | 2019 | 441 | 0.450 |
Why?
|
| Haplotypes | 2 | 2012 | 182 | 0.410 |
Why?
|
| Adenomatous Polyps | 1 | 2012 | 12 | 0.410 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 85 | 0.410 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2012 | 767 | 0.390 |
Why?
|
| Colonic Polyps | 1 | 2012 | 67 | 0.380 |
Why?
|
| Colonoscopy | 3 | 2019 | 104 | 0.380 |
Why?
|
| Male | 38 | 2022 | 20025 | 0.370 |
Why?
|
| Middle Aged | 28 | 2019 | 10129 | 0.360 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 9 | 0.360 |
Why?
|
| Tunica Media | 1 | 2009 | 12 | 0.360 |
Why?
|
| Patient Compliance | 3 | 2019 | 212 | 0.360 |
Why?
|
| Humans | 47 | 2022 | 37093 | 0.360 |
Why?
|
| Tunica Intima | 1 | 2009 | 19 | 0.350 |
Why?
|
| Brachial Artery | 1 | 2009 | 28 | 0.350 |
Why?
|
| Alcoholism | 5 | 2014 | 240 | 0.350 |
Why?
|
| Female | 35 | 2021 | 20969 | 0.340 |
Why?
|
| Blood Pressure | 3 | 2011 | 646 | 0.320 |
Why?
|
| Adult | 28 | 2021 | 11712 | 0.310 |
Why?
|
| Internship and Residency | 3 | 2015 | 125 | 0.310 |
Why?
|
| Research Subjects | 3 | 2021 | 32 | 0.300 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 204 | 0.290 |
Why?
|
| Regression Analysis | 5 | 2016 | 455 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2019 | 864 | 0.270 |
Why?
|
| Proglumide | 2 | 2022 | 3 | 0.260 |
Why?
|
| District of Columbia | 7 | 2019 | 71 | 0.260 |
Why?
|
| Aged | 18 | 2019 | 6741 | 0.250 |
Why?
|
| Exercise | 4 | 2016 | 613 | 0.250 |
Why?
|
| Biomedical Research | 2 | 2022 | 400 | 0.250 |
Why?
|
| Body Mass Index | 5 | 2011 | 854 | 0.240 |
Why?
|
| Endoscopy | 2 | 2014 | 14 | 0.230 |
Why?
|
| Appointments and Schedules | 2 | 2014 | 19 | 0.230 |
Why?
|
| Genetic Testing | 2 | 2014 | 75 | 0.210 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 59 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 628 | 0.200 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2021 | 3 | 0.200 |
Why?
|
| Urinary Incontinence | 1 | 2021 | 15 | 0.200 |
Why?
|
| Hypertension | 3 | 2005 | 796 | 0.200 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 198 | 0.200 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 2379 | 0.190 |
Why?
|
| Cognition | 3 | 2016 | 398 | 0.190 |
Why?
|
| Risk Assessment | 3 | 2018 | 753 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 3 | 2007 | 183 | 0.180 |
Why?
|
| Attitude to Health | 2 | 2014 | 325 | 0.180 |
Why?
|
| Outpatients | 3 | 2019 | 33 | 0.180 |
Why?
|
| Visual Acuity | 1 | 2020 | 97 | 0.180 |
Why?
|
| Ethanol | 2 | 2013 | 192 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 268 | 0.170 |
Why?
|
| Bacteria | 1 | 2022 | 255 | 0.160 |
Why?
|
| Patient Selection | 2 | 2021 | 164 | 0.160 |
Why?
|
| Specialties, Surgical | 1 | 2018 | 4 | 0.160 |
Why?
|
| Life Style | 2 | 2015 | 308 | 0.160 |
Why?
|
| Burnout, Professional | 1 | 2018 | 19 | 0.150 |
Why?
|
| Young Adult | 9 | 2015 | 4268 | 0.150 |
Why?
|
| Stroke | 2 | 2011 | 286 | 0.150 |
Why?
|
| United States | 9 | 2018 | 4223 | 0.150 |
Why?
|
| Referral and Consultation | 2 | 2015 | 117 | 0.150 |
Why?
|
| Mass Screening | 2 | 2019 | 462 | 0.150 |
Why?
|
| Normal Distribution | 1 | 2016 | 14 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 352 | 0.140 |
Why?
|
| Poisson Distribution | 1 | 2016 | 38 | 0.140 |
Why?
|
| Health Personnel | 1 | 2019 | 228 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2015 | 1492 | 0.140 |
Why?
|
| Apolipoprotein E4 | 1 | 2016 | 47 | 0.140 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 519 | 0.140 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 61 | 0.140 |
Why?
|
| China | 1 | 2016 | 196 | 0.140 |
Why?
|
| Substance-Related Disorders | 2 | 2015 | 730 | 0.140 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2013 | 10 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 336 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 127 | 0.130 |
Why?
|
| Psychotherapy, Brief | 1 | 2015 | 17 | 0.130 |
Why?
|
| Patient Dropouts | 1 | 2015 | 29 | 0.130 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2015 | 11 | 0.130 |
Why?
|
| Caloric Restriction | 1 | 2015 | 32 | 0.120 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 276 | 0.120 |
Why?
|
| Case-Control Studies | 4 | 2012 | 1130 | 0.120 |
Why?
|
| Risk Factors | 5 | 2012 | 3562 | 0.120 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 2721 | 0.120 |
Why?
|
| Phenotype | 3 | 2012 | 689 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2015 | 130 | 0.120 |
Why?
|
| Cultural Competency | 1 | 2015 | 131 | 0.120 |
Why?
|
| Semicarbazides | 1 | 2013 | 2 | 0.120 |
Why?
|
| Hydrazones | 1 | 2013 | 5 | 0.120 |
Why?
|
| Age Factors | 3 | 2018 | 1033 | 0.120 |
Why?
|
| Erythrocyte Membrane | 1 | 2013 | 20 | 0.120 |
Why?
|
| Quality of Life | 1 | 2018 | 481 | 0.110 |
Why?
|
| Algorithms | 1 | 2016 | 465 | 0.110 |
Why?
|
| Adolescent | 7 | 2015 | 5363 | 0.110 |
Why?
|
| Iron Chelating Agents | 1 | 2013 | 21 | 0.110 |
Why?
|
| Nutrition Surveys | 2 | 2012 | 242 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 29 | 0.110 |
Why?
|
| Mortality | 2 | 2011 | 145 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 69 | 0.110 |
Why?
|
| Gene Frequency | 2 | 2012 | 195 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2015 | 339 | 0.110 |
Why?
|
| Urban Population | 2 | 2012 | 333 | 0.110 |
Why?
|
| Antimalarials | 1 | 2013 | 55 | 0.110 |
Why?
|
| Job Application | 1 | 2012 | 3 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2012 | 11 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2012 | 534 | 0.110 |
Why?
|
| Ophthalmology | 1 | 2012 | 29 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 55 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2012 | 66 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 191 | 0.110 |
Why?
|
| Career Choice | 1 | 2012 | 45 | 0.100 |
Why?
|
| Plasmodium falciparum | 1 | 2013 | 135 | 0.100 |
Why?
|
| Vitamins | 1 | 2012 | 94 | 0.100 |
Why?
|
| Introns | 1 | 2012 | 75 | 0.100 |
Why?
|
| Exons | 1 | 2012 | 88 | 0.100 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 74 | 0.100 |
Why?
|
| Cotinine | 1 | 2011 | 43 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2021 | 1378 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2013 | 305 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 583 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 515 | 0.100 |
Why?
|
| Dilatation, Pathologic | 1 | 2009 | 9 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 70 | 0.090 |
Why?
|
| Vasodilation | 1 | 2009 | 65 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2009 | 117 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2009 | 112 | 0.090 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2009 | 12 | 0.080 |
Why?
|
| Medical Staff, Hospital | 1 | 2009 | 13 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2009 | 36 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2009 | 34 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 103 | 0.080 |
Why?
|
| Logistic Models | 1 | 2012 | 923 | 0.080 |
Why?
|
| Alcoholic Beverages | 1 | 2008 | 15 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 225 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2009 | 53 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2009 | 550 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 372 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 237 | 0.080 |
Why?
|
| Prevalence | 4 | 2019 | 1455 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 75 | 0.070 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 19 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 205 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2005 | 23 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2303 | 0.060 |
Why?
|
| Alleles | 3 | 2016 | 321 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 643 | 0.060 |
Why?
|
| Smoking | 1 | 2011 | 940 | 0.060 |
Why?
|
| Lipoprotein(a) | 1 | 2004 | 5 | 0.060 |
Why?
|
| Linear Models | 1 | 2005 | 275 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 36 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 974 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2015 | 2026 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Cholecystokinin | 1 | 2022 | 16 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 52 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 1 | 2002 | 34 | 0.050 |
Why?
|
| Lipids | 1 | 2004 | 235 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 94 | 0.050 |
Why?
|
| Mental Recall | 2 | 2012 | 78 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 159 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 43 | 0.050 |
Why?
|
| Curriculum | 2 | 2015 | 265 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 92 | 0.050 |
Why?
|
| Neoplasms | 1 | 2011 | 1103 | 0.050 |
Why?
|
| Exercise Therapy | 2 | 2016 | 69 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 47 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 898 | 0.050 |
Why?
|
| Hemolysis | 2 | 2013 | 40 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2016 | 661 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2022 | 133 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1067 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 562 | 0.040 |
Why?
|
| Cathartics | 1 | 2019 | 6 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 922 | 0.040 |
Why?
|
| Liver | 1 | 2022 | 479 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 84 | 0.040 |
Why?
|
| Stereotyping | 1 | 2019 | 40 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 75 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 644 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2011 | 63 | 0.040 |
Why?
|
| Prejudice | 1 | 2019 | 110 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 485 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2022 | 808 | 0.040 |
Why?
|
| Prognosis | 2 | 2013 | 739 | 0.040 |
Why?
|
| Cholesterol, HDL | 2 | 2011 | 97 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 596 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 373 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1609 | 0.040 |
Why?
|
| Heterozygote | 1 | 2016 | 93 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 1371 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 1015 | 0.030 |
Why?
|
| Comorbidity | 2 | 2009 | 623 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 25 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 420 | 0.030 |
Why?
|
| Diet, Reducing | 2 | 2005 | 24 | 0.030 |
Why?
|
| Hospitals | 1 | 2014 | 86 | 0.030 |
Why?
|
| Research Personnel | 1 | 2015 | 155 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 1742 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 47 | 0.030 |
Why?
|
| Breath Tests | 1 | 2013 | 24 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 67 | 0.030 |
Why?
|
| Siblings | 1 | 2013 | 18 | 0.030 |
Why?
|
| Communication | 1 | 2015 | 180 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 935 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 54 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2012 | 86 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 441 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2011 | 34 | 0.030 |
Why?
|
| Seasons | 1 | 2012 | 112 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 30 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 142 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 2012 | 169 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 893 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 182 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 5913 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 195 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 267 | 0.020 |
Why?
|
| Women's Health | 1 | 2010 | 145 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2012 | 294 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 44 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 75 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 55 | 0.020 |
Why?
|
| Awareness | 1 | 2009 | 65 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 108 | 0.020 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2008 | 3 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2008 | 61 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2007 | 7 | 0.020 |
Why?
|
| Hematocrit | 1 | 2007 | 18 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 2007 | 13 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2007 | 12 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 253 | 0.020 |
Why?
|
| Bilirubin | 1 | 2007 | 17 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 61 | 0.020 |
Why?
|
| Child | 2 | 2007 | 3131 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 37 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 62 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 215 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2006 | 1 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2009 | 208 | 0.020 |
Why?
|
| Autopsy | 1 | 2006 | 43 | 0.020 |
Why?
|
| Violence | 1 | 2008 | 134 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 1369 | 0.020 |
Why?
|
| Health Promotion | 1 | 2012 | 653 | 0.020 |
Why?
|
| Cause of Death | 1 | 2006 | 156 | 0.020 |
Why?
|
| Universities | 1 | 2009 | 442 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2006 | 104 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 15081 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 44 | 0.010 |
Why?
|
| Students | 1 | 2009 | 519 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 2004 | 62 | 0.010 |
Why?
|
| Triglycerides | 1 | 2004 | 138 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 77 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 205 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2002 | 24 | 0.010 |
Why?
|
| Nigeria | 1 | 2002 | 86 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 92 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 142 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 1908 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 997 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2002 | 387 | 0.010 |
Why?
|